bexarotene has been researched along with mdv 3100 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dar, JA; Eisermann, K; Feturi, FG; Johnston, PA; Kenefake, AN; Masoodi, KZ; Nelson, JB; Nguyen, M; O'Malley, K; Parrinello, E; Pascal, LE; Wang, Z; Wipf, P; Yang, Z | 1 |
1 other study(ies) available for bexarotene and mdv 3100
Article | Year |
---|---|
Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Topics: Androgen Receptor Antagonists; Animals; Benzamides; Bexarotene; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Nitriles; Phenylthiohydantoin; Piperazines; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2017 |